The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 351-358

  Molina, Jean Michel ^a   Chêne, Geneviève ^b   Ferchal, Françoise ^a   Journot, Valérie ^b   Pellegrin, Isabelle ^c   Sombardier, Marie Noëlle ^a   Rancinan, Corinne ^b   Cotte, Laurent ^d   Madelaine, Isabelle ^a   Debord, Thierry ^e   Decazes, Jean Marie ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL PELLEGRIN   (France)

^d HÔTEL DIEU   (France)

^e SERVICE D ENDOCRINOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MYALGIA; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE; TREATMENT OUTCOME; VIREMIA; ZIDOVUDINE;

EID: 0033502897     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314891     Document Type: Article

References (23)

1. 1. US Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47:43-82.
2. 2. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 1998;280:78-86.
3. 3. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294-8.
4. 4. Hogg RS, Heath KV. Yip B. et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279: 450-4.
5. 5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
6. 6. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
7. 7. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348: 283-91.
8. 8. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
9. 9. Banlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with infection: a randomized double-blind, placebo-controlled trial. Ann Intern Med 1996; 125:161-72.
10. 10. Foudraine NA, de Jong JJ, Weverling GJ, et al. An open randomized trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS 1998;12:1513-19.
11. 11. Dolin R, Amato D, Fischl MA, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine, Arch Intern Med 1995;155:961-74.
12. 12. Staszewski S, Loveday C, Picazo J, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA 1996;276:111-7.
13. 13. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349: 1413-21.
14. 14. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4 + cells per cubic millimeter. N Engl J Med 1995;335:1662-9.
15. 15. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudme combination therapy in antiretroviral-naive patients: a randomised controlled comparison with zidovuine monotherapy. JAMA 1996;276:118-25.
16. 16. Pollard R, Peterson D, Hardy D, et al. Antiviral effect and safety of stavudine (stavudine) and didanosine (didanosine) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blind trial. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.
17. 17. Reynes J, Denisi R, Bicart-See A, et al. STADI; sustained efficacy of once daily administration of didanosine in combination with stavudine. Presented at the 12th World AIDS Conference, Geneva, 28 June-3 July, 1998 (abstract 12351).
18. 18. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996; recommendations of an international panel. JAMA 1996;276:146-54.
19. 19. Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:446-54.
20. 20. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
21. 21. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997;41: 284-91.
22. 22. Jung M, Agut H, Candotti D, Ingrand D, Katlama C, Huraux JM. Susceptibility of HTV-1 isolates to zidovudine; correlation between widely applicable culture test and PCR analysis. J Acquir Immune Defic Syndr 1992;5:359-64.
23. 23. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV-infection. AIDS 1998;12:F71-7.